Forward Pharma A/S ADR Stock (OTC: FWPAY)

Latest news for Forward Pharma A/S ADR (OTC:FWPAY) Stock

Forward Pharma A/S ADR

DA Davidson analyst Linda Bolton Weiser maintains Helen Of Troy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) with a Buy and maintains $139 price target.

News

Price Target

Analyst Ratings

HELE

DA Davidson Maintains Buy on Helen Of Troy, Maintains $139 Price Target

This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017. This is the fourth option exercise by Taiho to an Arcus program.
In exchange for the exclusive license of quemliclustat, Taiho will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and commercialization milestones, and, if any products from the program are approved, will pay royalties on net sales of such products.

RCUS

Arcus Biosciences Says Taiho Exercised Its Option For Quemliclustat In Japan And Certain Other Territories In Asia (Excluding Mainland China)

PEGY

Pineapple Energy Engages Conduit Capital To Provide Structural Internal Support, Staffing, And Assistance With Capital Raising Activities

CSX will release&nbsp;second quarter&nbsp;financial and operating results after the market close on Monday, August 5, 2024.
This release date reflects the Company&#39;s review of the capitalization of prior period engineering materials and labor.
The results of this review are not expected to impact free cash flow in past or future periods. Excluding the results of this review, the Company still expects to improve both operating income and operating margin on a sequential basis in the&nbsp;second quarter, and management will provide more details on the earnings call.

Guidance

CSX Reports Review Of Capitalization Of Prior Period Engineering Materials And Labor; Expects Results Of This Review Not To Impact Free Cash Flow In Past Or Future Periods

The 70-bed inpatient rehabilitation hospital, located at 1355 Independence Drive, was purchased by Encompass Health in 2013.

Piedmont, Encompass Health Expand Existing JV Arrangement To Include Walton Rehabilitation Hospital, In Augusta, Georgia

For consumers, one of the most important determining factors when it comes to buying a new vehicle is often price, which is a trend that is constantly monitored by the <a href="https://www.benzinga.com/electric-vehicles">electric vehicle sector.</a>
One state may have a solution for increased adoption.
What Happened: The state of Colorado is considered one of <a href="https://www.benzinga.com/news/23/08/33589652/tesla-vehicle-for-under-15-000-not-yet-but-this-state-has-incentives-to-get-the-price-under-20-000">the most friendly </a>when it comes to electric vehicle adoption and a new offer from a local car dealership could strengthen that point across America.
A Colorado Nissan dealer is offering a new leasing special offering the 2025 Nissan LEAF S for $19 per month. The offer is good for 24 months with $0 down and 10,000 miles annually.
The family-owned Tynan's Nissan Aurora is the dealership behind the special, as reported by <a href="https://electrek.co/2024/07/05/lease-2025-nissan-leaf-19-dollars-a-month/">Electrek</a>.
The dealership is <a href="https://www.tynansnissanaurora.com/new-specials/">offering </a>60 vehicles as part of the deal.
The $19 per month fee comes with a slight catch, depending on how a consumer makes their purchase. While no down payment is required, a consumer is responsible for a $695 acquisition fee and a $699 dealer handling fee. These fees, along with the first payment due at signing, can be rolled into the lease taking the monthly total up to $79 per month. This figure also doesn't include taxes.
Read Also: <a href="https://www.benzinga.com/news/24/05/39104987/americans-cling-to-gas-cars-over-evs-even-at-equal-prices-survey-reveals-whats-the-biggest-factor">Americans Cling To Gas Cars Over EVs Even At Equal Prices, Survey Reveals: What&#8217;s The Biggest Factor?</a>
Why It's Important: Colorado offers an $8,100 state EV tax credit, which is part of the lease offer, along with national credits and other state credits.
Benzinga previously shared that Colorado was offering incentives that took the starting price of a Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Model 3 RWD from $40,240 down to $13,740 or $19,240, depending on if all credits were stackable.
Colorado Gov. Jared Polis is pushing to have one million plug-in electric vehicles on Colorado roads by 2030. The governor wants to see electric vehicles consist of 25% of new car sales in the state by 2025, compared to 13% in mid-2023.
The 2025 Nissan LEAF S is one of several electric vehicles from Nissan, which is a unit of Renault ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RNLSY#OTC">RNLSY</a>), as the company works on delivering affordable EVs to consumers.
The vehicle has a starting price of $28,140 before credits, according to the company.
Tesla offers <a href="https://www.tesla.com/support/leasing-your-vehicle#credit">leasing </a>on several models with its Model 3 RWD offered for around $299 per month with $2,999 due at signing.
The electric vehicle giant also<a href="https://www.benzinga.com/news/24/05/38798863/tesla-defies-auto-industry-trends-with-0-99-apr-model-y-financing-offer"> offered a limited time </a>0.99% APR on the Tesla Model Y in the month of May.
New financing offers and lease specials combined with state and federal tax credits could make new electric vehicles more affordable for most consumers.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39595720/tesla-deliveries-fall-for-second-straight-quarter-but-stock-takes-off-as-q2-numbers-exceed-expec">Tesla Deliveries Fall For Second Straight Quarter, But Stock Takes Off As Q2 Numbers Exceed Expectations</a></li>
</ul>

Photo: 2025 Nissan LEAF, Courtesy Nissan

Small Business

RNLSY

TSLA

Electric Vehicle Lease For $19 A Month? Dealership In This State Has New Offer To Lure Customers

The business will operate as a full-service managing general underwriter under Amynta Risk Solutions.&nbsp;
The business provides medical stop loss coverage to a diversified group of employers and industries across the United States.&nbsp;&nbsp;
The transaction is expected to close in the&nbsp;third quarter&nbsp;of 2024, subject to customary closing conditions.&nbsp;

Asset Sales

Amynta Group To Acquire Unum Group's Medical Stop Loss Business; Terms Not Disclosed

Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) has outperformed the market over the past 10 years by 5.31% on an annualized basis producing an average annual return of 16.22%. Currently, Ross Stores has a market capitalization of $48.99 billion. 
Buying $100 In ROST: If an investor had bought $100 of ROST stock 10 years ago, it would be worth $450.94 today based on a price of $146.70 for ROST at the time of writing.
<h3>Ross Stores's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720474235_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ROST

Here's How Much You Would Have Made Owning Ross Stores Stock In The Last 10 Years

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 12.02% on an annualized basis producing an average annual return of 22.93%. Currently, Meta Platforms has a market capitalization of $1.34 trillion. 
Buying $1000 In META: If an investor had bought $1000 of META stock 10 years ago, it would be worth $7,795.58 today based on a price of $529.63 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720474230_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Meta Platforms 10 Years Ago Would Be Worth Today

Matosevic&#39;s leave is pending completion of an ongoing investigation being conducted by the Board with the assistance of outside legal counsel. Helios will make further announcements regarding this matter when the Board approves any course of action for which further disclosure is appropriate.
The alleged conduct that prompted this review does not relate to, and does not impact, the Company&#39;s strategy or financial reporting.

Management

HLIO

Helios Reports Board's Decision To Place Josef Matosevic, President, CEO And Director, On Paid Leave, Due To Allegations Of Potential Violation Of Code Of Business Conduct And Ethics

This compares to&nbsp;$42.80&nbsp;per share at March 31, 2024,&nbsp;$42.11&nbsp;per share at December 31, 2023 and&nbsp;$41.41&nbsp;per share at June 30, 2023.

Associated Capital Reports Preliminary Range For Its Q2 Book Value Of $42.75 To $42.95 Per Share

Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares traded higher Monday. President Joe Biden told congressional Democrats that he will continue his reelection<a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39625294/2024-election-betting-odds-react-to-biden-debate-disaster-trump-odds-hit-all-time-high-kam"> campaign in a letter on Monday. </a>
<h1 class="wp-block-heading">The Details</h1>
In a letter to Democrats in Congress, President Biden said that he remains <a href="https://www.documentcloud.org/documents/24794149-biden-letter-to-congressional-democrats">fully committed</a> to continuing his presidential campaign despite concerns regarding his mental fitness and ability to beat Donald Trump in the election. 
"I want you to know that despite all the speculation in the press and elsewhere, I am firmly committed to staying in this race, to running this race to the end, and to beating Donald Trump," Biden wrote.&nbsp;
Read Next:<a href="https://www.benzinga.com/news/24/07/39648950/whats-going-on-with-arm-holdings-stock"> What&#8217;s Going On With Arm Holdings Stock?</a>
Biden's letter to Democrats comes as he attempts to unite the party behind his campaign before the Democratic National Convention, scheduled to begin Aug. 19 in Chicago. 
"It's time to come together, move forward as a unified party, and defeat Donald Trump," Biden wrote.&nbsp;
Republicans will gather next week in Milwaukee for the Republican National Convention where the party will officially nominate its candidate for President, presumptively Trump after he crossed the majority delegate threshold necessary for the nomination back in March. 
Trump Media &amp; Technology stock rose following reports of Biden's letter to Democrats, possibly because <a href="https://www.benzinga.com/government/24/07/39663724/whats-going-on-with-trump-media-technology-group-stock-on-monday">investors view</a> Biden remaining in the race as good news for Trump's campaign. According to Covers, the <a href="https://www.covers.com/politics/us-election-betting-odds">odds </a>of Trump winning the 2024 election stand at -175 with an implied probability of 63%. 
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Trump Media &amp; Technology shares are trading below the stock&#8217;s 50-day moving average of $42.96 and are down 32% over the past month.&nbsp;
<h1 class="wp-block-heading">Should I Sell My DJT Stock?</h1>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Trump Media &amp; Technology have increased by 125.43% in the past year. An investor who bought shares of Trump Media &amp; Technology at the beginning of the year would have made a profit of $12.87 per share if they sold it today. The stock has fallen 27.96% over the past month, meaning an investor who bought shares on June 1 would see a capital loss of $16.42.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Trump Media &amp; Technology stock currently has an RSI of 26.27, indicating oversold conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
DJT Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Trump Media &amp; Technology Group shares ended Monday's session 3.94% higher at $30.32.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39650853/whats-going-on-with-palantir-stock">What&#8217;s Going On With Palantir Stock?</a></li>
</ul>
Image: Shutterstock

Government

Politics

Movers

What Happened With Trump Media & Technology Group Stock Today?

All of the securities to be sold in the offering are to be offered by Tonix.&nbsp;The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya&trade; product candidate in patients with fibromyalgia, and the satisfaction of any portion of its existing indebtedness.

Offerings

TNXP

Tonix Pharmaceuticals Intends To Offer And Sell Shares Of Its Common Stock Or Pre-funded Warrants In Lieu Thereof

Across the recent three months, 15 analysts have shared their insights on American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for American Express, presenting an average target of $245.93, a high estimate of $280.00, and a low estimate of $175.00. Marking an increase of 5.68%, the current average surpasses the previous average price target of $232.71. 
<img src="https://www.benzinga.com/files/images/story/2024/1720472468_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of American Express by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$268.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$250.00</td>
<td>-</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$263.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>David George</td>
<td>Baird</td>
<td>Raises</td>
<td>Underperform</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$255.00</td>
<td>$243.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Moshe Orenbuch</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$225.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$253.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Mark Devries</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>James Fotheringham</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Underperform</td>
<td>$175.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$226.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Saul Martinez</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$239.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to American Express. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of American Express compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for American Express's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into American Express's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AXP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on American Express analyst ratings.</a>
<h2>All You Need to Know About American Express</h2>
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. Since 2018, it has operated in three segments: global consumer services, global commercial services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.
<h3>Key Indicators: American Express's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: American Express displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 10.64%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: American Express's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.22%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): American Express's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.47%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): American Express's ROA excels beyond industry benchmarks, reaching 0.91%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.76.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 15 Takes On American Express

AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for AT&amp;T, presenting an average target of $21.79, a high estimate of $26.00, and a low estimate of $17.00. This upward trend is apparent, with the current average reflecting a 2.16% increase from the previous average price target of $21.33.
<img src="https://www.benzinga.com/files/images/story/2024/1720472456_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of AT&amp;T's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Bryan Kraft</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Timothy Horan</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>John Hodulik</td>
<td>UBS</td>
<td>Maintains</td>
<td>Buy</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$22.50</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AT&amp;T. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AT&amp;T compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of AT&amp;T's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of AT&amp;T's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/T/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AT&amp;T analyst ratings.</a>
<h2>About AT&amp;T</h2>
The wireless business contributes about two thirds of AT&amp;T's revenue. The firm is the third-largest US wireless carrier, connecting 72 million postpaid and 17 million prepaid phone customers. Fixed-line enterprise services, which account for about 16% of revenue, include internet access, private networking, security, voice, and wholesale network capacity. Residential fixed-line services, about 11% of revenue, primarily consist of broadband internet access, serving 14 million customers. AT&amp;T also has a sizable presence in Mexico, with 22 million customers, but this business only accounts for 3% of revenue. The firm still holds a 70% equity stake in satellite television provider DirecTV but does not consolidate this business in its financial statements.
<h3>AT&amp;T's Economic Impact: An Analysis</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Decline in Revenue: Over the 3 months period, AT&amp;T faced challenges, resulting in a decline of approximately -0.37% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: AT&amp;T's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 11.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AT&amp;T's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.27%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.84%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: AT&amp;T's debt-to-equity ratio stands notably higher than the industry average, reaching 1.44. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 7 Analyst Recommendations For AT&T

Arcus Biosciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Arcus Biosciences, presenting an average target of $34.25, a high estimate of $44.00, and a low estimate of $25.00. Observing a downward trend, the current average is 9.27% lower than the prior average price target of $37.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1720472446_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Arcus Biosciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Robert Driscoll</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Arcus Biosciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Arcus Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Arcus Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Arcus Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RCUS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Arcus Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Arcus Biosciences: A Closer Look</h2>
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
<h3>Arcus Biosciences: Financial Performance Dissected</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Arcus Biosciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 480.0% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Arcus Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2.76%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Arcus Biosciences's ROE stands out, surpassing industry averages. With an impressive ROE of -0.68%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Arcus Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.34% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Arcus Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences

6 analysts have shared their evaluations of Interactive Brokers Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $139.33, along with a high estimate of $152.00 and a low estimate of $125.00. Witnessing a positive shift, the current average has risen by 9.99% from the previous average price target of $126.67.
<img src="https://www.benzinga.com/files/images/story/2024/1720472435_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Interactive Brokers Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Fannon</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Daniel Fannon</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$136.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$152.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Interactive Brokers Gr. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Interactive Brokers Gr compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Interactive Brokers Gr's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IBKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Interactive Brokers Gr analyst ratings.</a>
<h2>Delving into Interactive Brokers Gr's Background</h2>
Interactive Brokers is an online brokerage that generates trading commissions (around 31% of net revenue) from facilitating trading in a wide range of products, including equity, options, futures, foreign exchange, bonds, mutual funds, and ETFs. Interactive Brokers also generates net interest income (about 64% of net revenue) from idle client cash and earns fees (about 6% of net revenue) from ancillary services. Principal trading and other miscellaneous activities are small (about 5% of net revenue). The firm derives about 70% of its net revenue from the U.S. and 30% from international markets.
<h3>Breaking Down Interactive Brokers Gr's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Interactive Brokers Gr displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 25.82%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Interactive Brokers Gr's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 7.96%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.78%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Interactive Brokers Gr's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.13%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IBKR

The Analyst Landscape: 6 Takes On Interactive Brokers Gr

5 analysts have shared their evaluations of Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $45.4, a high estimate of $53.00, and a low estimate of $42.00. Observing a 10.06% increase, the current average has risen from the previous average price target of $41.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1720472423_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Viper Energy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Aaron Bilkoski</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$44.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Viper Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Viper Energy compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Viper Energy's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Viper Energy's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VNOM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Viper Energy analyst ratings.</a>
<h2>Get to Know Viper Energy Better</h2>
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties primarily in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
<h3>Financial Milestones: Viper Energy's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Viper Energy's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 21.76%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Viper Energy's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.1% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Viper Energy's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.14% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Viper Energy's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.08%, the company showcases efficient use of assets and strong financial health.
Debt Management: Viper Energy's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.01, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VNOM

Peeling Back The Layers: Exploring Viper Energy Through Analyst Insights

Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) has outperformed the market over the past 5 years by 6.91% on an annualized basis producing an average annual return of 19.96%. Currently, Red Rock Resorts has a market capitalization of $3.31 billion. 
Buying $100 In RRR: If an investor had bought $100 of RRR stock 5 years ago, it would be worth $257.89 today based on a price of $55.55 for RRR at the time of writing.
<h3>Red Rock Resorts's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720472420_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Red Rock Resorts 5 Years Ago Would Be Worth Today

Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) has outperformed the market over the past 5 years by 23.16% on an annualized basis producing an average annual return of 36.22%. Currently, Axon Enterprise has a market capitalization of $22.83 billion. 
Buying $1000 In AXON: If an investor had bought $1000 of AXON stock 5 years ago, it would be worth $4,807.37 today based on a price of $302.48 for AXON at the time of writing.
<h3>Axon Enterprise's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720472415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.